Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Wellcome Will Close Research Institute in Geneva Next Year


LONDON--Pharmaceutical company Glaxo Wellcome here has announced plans to close its Biomedical Research Institute in Geneva, Switzerland, by the end of April. Efforts at the site are focused on molecular biology and it houses some of the company's bioinformatics staff, but it isn't the hub for Glaxo's bioinformatics efforts.

The decision came after a review of the company's research strategy that recommended concentrating R&D efforts in France, Italy, Japan, Spain, the UK, and the US, according to Glaxo, which has owned the Geneva business for the past 10 years. One reason for the closure is that molecular biology activities are increasingly being integrated into technological approaches, such as bioinformatics and genomics, the company said.

Filed under